Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 0.32% 15.55 15.00 16.00 16.00 15.50 15.50 86,782 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 78.2 8.1 1.1 14.0 99

Allergy Therapeutics PLC Grant of Awards under Long Term Incentive Plan

20/11/2020 1:51pm

UK Regulatory (RNS & others)


Allergy Therapeutics (LSE:AGY)
Historical Stock Chart


From Oct 2020 to Nov 2020

Click Here for more Allergy Therapeutics Charts.

TIDMAGY

RNS Number : 0593G

Allergy Therapeutics PLC

20 November 2020

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Grant of Awards under Long Term Incentive Plan

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, o n 20 November 2020, pursuant to the Company's Long Term Incentive Plan ("LTIP") t he following conditional awards of shares of 0.1 pence each were made to Executive Directors at a nominal cost of 0.1 pence each (the "Awards").

 
 Executive Director    Number of Conditional shares 
                        awarded 
 Manuel Llobet                   900,000 
                      ----------------------------- 
 Nick Wykeman                    450,000 
                      ----------------------------- 
 

The Awards have been granted in accordance with the LTIP rules and vesting is conditional on the satisfaction of two performance measures over a three-year period:

 
 Measure:                                  Target Range: 
 Compounded annual earnings growth rate    7.5% - 17.5% 
  (EBITDA) pre R&D spend 
                                          -------------- 
 Compounded annual share price growth      15% - 40% 
                                          -------------- 
 

Following the above share transactions, the Executive Directors hold the following:

 
 Director           Unvested LTIP   Low cost Share   Interest in Ordinary 
                     Awards          Options          Shares 
 Manuel Llobet      3,600,000       211,250          3,325,000 
                   --------------  ---------------  --------------------- 
 Nicolas Wykeman    1,800,000       211,250          300,000 
                   --------------  ---------------  --------------------- 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Manuel Llobet 
     ---------------------  ------------------------------------------------ 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status        Manuel Llobet - Chief Executive Office and PDMR 
     ---------------------  ------------------------------------------------ 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------------ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                   ALLERGY THERAPEUTICS PLC 
     ---------------------  ------------------------------------------------ 
 b)   LEI                    LEIR97215202003301009534776 
     ---------------------  ------------------------------------------------ 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ----------------------------------------------------------------------- 
 a)   Description            Conditional award of shares under the Company's 
       of the financial       Long Term Incentive Plan 
       instrument, 
       type of instrument 
     ---------------------  ------------------------------------------------ 
 b)   Identification         GB00B02LCQ05 
       code 
     ---------------------  ------------------------------------------------ 
 c)   Nature of the          Grant of Conditional Awards 
       transaction 
     ---------------------  ------------------------------------------------ 
 d)   Price(s) and            Award                 Price(s)    Volume(s) 
       volume(s)               Conditional Shares    GBP0.001    900,000 
     ---------------------  ------------------------------------------------ 
 e)   Aggregated 
       information              n/a 
     ---------------------  ------------------------------------------------ 
 f)   Date of the            19 November 2020 
       transaction 
     ---------------------  ------------------------------------------------ 
 g)   Place of the           Outside a trading venue 
       transaction 
     ---------------------  ------------------------------------------------ 
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                   Nick Wykeman 
     ---------------------  ------------------------------------------------ 
 2    Reason for the notification 
     ----------------------------------------------------------------------- 
 a)   Position/status        Nick Wykeman - Chief Financial Officer and PDMR 
     ---------------------  ------------------------------------------------ 
 b)   Initial notification   Initial notification 
       /Amendment 
     ---------------------  ------------------------------------------------ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------- 
 a)   Name                   ALLERGY THERAPEUTICS PLC 
     ---------------------  ------------------------------------------------ 
 b)   LEI                    LEIR97215202003301009534776 
     ---------------------  ------------------------------------------------ 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ----------------------------------------------------------------------- 
 a)   Description            Conditional award of shares under the Company's 
       of the financial       Long Term Incentive Plan 
       instrument, 
       type of instrument 
     ---------------------  ------------------------------------------------ 
 b)   Identification         GB00B02LCQ05 
       code 
     ---------------------  ------------------------------------------------ 
 c)   Nature of the          Grant of Conditional Awards 
       transaction 
     ---------------------  ------------------------------------------------ 
 d)   Price(s) and            Award                 Price(s)    Volume(s) 
       volume(s)               Conditional Shares    GBP0.001    450,000 
     ---------------------  ------------------------------------------------ 
 e)   Aggregated 
       information              n/a 
     ---------------------  ------------------------------------------------ 
 f)   Date of the            19 November 2020 
       transaction 
     ---------------------  ------------------------------------------------ 
 g)   Place of the           Outside a trading venue 
       transaction 
     ---------------------  ------------------------------------------------ 
 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Erik Anderson, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines, that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBXBDBISDDGGG

(END) Dow Jones Newswires

November 20, 2020 08:51 ET (13:51 GMT)

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart
ADVFN Advertorial
Your Recent History
LSE
AGY
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201127 01:15:46